INTRODUCTION
Hydrogen sulfide (H 2 S), recognized as a new gaseous mediator, plays numerous roles both in normal physiological and pathophysiological conditions).
Three enzymes endogenously synthesize H 2 S: cystathionine-ß-synthase (CBS), cystathionine-γ-lyase (or cystathionase, CSE) and 3-mercapto-sulphurtransferase (2, 3) . H 2 S plays numerous roles both in normal physiological and pathophysiological conditions (1) . As nitric oxide (NO), H 2 S is involved in the regulation of vascular tone. Experimental evidence has shown that H 2 S evokes concentration-dependent relaxation of many vascular districts, such as the aorta, through ATP-sensitive potassium (K+ATP)-channels opening (4), the portal vein (5) , and the mesenteric artery bed (6) . In particular, according to the Authors, the sensitivity of mesenteric artery bed to H 2 S was about fivefold higher than in the aorta in rats. The supposed H 2 S-selectivity for the mesenteric vascular system has recently been confirmed. Yang et al. demonstrated that CSE knock-out mice displayed hypertension and diminished endothelium-dependent vascular relaxation, which were more pronounced in the mesenteric district (7) . Decreased mesenteric perfusion is a severe complication occurring in critically ill patients (8, 9) . The mesenteric hypoperfusion can be linked to an increase in intraabdominal pressure (e.g. traumatic injury, retroperitoneal hematoma) or shock. The switch from aerobic to anaerobic metabolism in the mesenteric bed promotes the secretion of multiple vasoactive substances (e.g. nitric oxide) to improve tissue perfusion through local vasodilation. Eventually, persistent vasodilation may adversely affect both macro-and microcirculation, leading to tissue hypoperfusion (10) . In mechanically ventilated patients affected by acute respiratory distress syndrome, high respiratory pressures, including positive end-expiratory pressure (PEEP), may exacerbate mesenteric hypoperfusion (10) . High PEEP may lead to both regional and systemic adverse effects due to increased intra-thoracic pressures and decreased venous return to right atrium (11) . The consequent reduction in cardiac output redistributes blood flow away from the splanchnic circulation with an elevated risk for mesenteric ischemia, as already confirmed in rodents and pigs (11) . The aim of the present study was to examine the effect of incremental intravenous doses of sodium hydrogen sulfide (NaHS), a H 2 S donor, within a physiological range on pig mesenteric microcirculatory blood flow in both physiological and PEEP-induced ischemic conditions.
METHODS

Animals and compounds.
Fourteen male pigs, weight 10 Kg±1 (SEM), were used with the approval of the Local Animal Experiment Ethics Committee. All procedures were carried out according to the guidelines of the National Institute of Health for the care and use of laboratory animals. As a source of H 2 S in sodium-chloride solution (0.9%, vehicle), we used sodium hydrogen sulfide (NaHS, Sigma-Aldrich Srl, Milano, Italy), which reacts with water (1 ml/kg), producing H 2 S (5). Anesthesia. After overnight fast, pigs were anesthetized with ketamine (10 mg/Kg i.m.) and maintained under anesthesia with nitrous oxide (N 2 O) and sevoflurane (Sevorane ® , Baxter) at 1.0 MAC. Neuromuscular block was achieved with a bolus of vecuronium bromide (0.1 mg/kg) and maintained with additional boluses of 0.015 mg/kg every 30 min. Animals were intubated in a supine position with a 4.5-5.0 mm inner diameter cuffed endotracheal tube and mechanically ventilated with tidal volume of 8 ml/kg and FiO 2 set at 50%. The following physiological parameters were monitored: 1) electrocardiogram (lead DII); 2) inspired and expired oxygen and carbon dioxide concentrations (%); 3) SpO 2 (ear lobe); 4) invasive femoral arterial pressure (20 G).
Surgical preparation. A mini-laparotomy was performed to expose the Treitz muscle. The Treitz muscle was sectioned to access the jejunum. In order to evaluate the mesenteric perfusion, a laser Doppler flowmeter probe was positioned in the first jejunal loop (12) . For better evaluation, the probe was placed near a micro-vessel on the same course of mesenteric artery root and kept in place with a 3/0 Dexon suture. A second Doppler flowmeter probe was placed on the sternal skin to measure cutaneous perfusion. At the end of each experimental surgery, the mini-laparotomy was sutured and the animal was sacrificed with an intravenous bolus of KCl. Experimental protocol. The study protocol is summarized in Figure 1 . Panel A and Panel B illustrate respectively the experimental protocol for both control and ischemia-induced groups. In the ischemia groups, a PEEP of 15 cmH 2 O was applied to achieve mesenteric hypo-perfusion, as according to many other similar study protocols (13, 14) . The administration of the drug was shifted 40 minutes later than the control group in order to achieve hemodynamic stabilization.
An intravenous bolus of NaHS (10 ml) was administrated at a constant rate of 60 seconds every 20 minutes in the following order: 1 µM/kg, 3 µM/kg, 10 µM/kg, 30 µM/kg, 100 µM/kg, 300 µM/kg, 1000 µM/kg. No artifact signal due to the injection procedure has been noticed. In both groups, the baseline measurements were performed twenty minutes after the induction of anesthesia (stabilization period), and subsequently repeated 10 minutes after each NaHS administration. In both groups, mesenteric perfusion was recorded from the end of the stabilization period until the death of the animal ( Figure 1 panel  A and B) . Laser Doppler Flow Measurements. In order to measure the tissue perfusion, a Laser Doppler Flowmeter (Periflux System 5000, Perimed, Milan, Italy) was used, with a small straight probe (probe 407-1) on the sternal skin and a needle probe (probe Heart, Lung and Vessels. 2015, Vol.7 411) in the jejunal mucosa (see above). Basal blood flow was defined as the mean of blood flow (expressed as Perfusion Unit, PU) within a 10-minute interval immediately after the stabilization period. The response to each NaHS dose was expressed as the mean of blood flow (expressed as Perfusion Unit, PU). Changes in blood flow were expressed as percentage increases relative to the basal level. For the ischemia group, we considered as basal level the mean blood flow within a 10 minutes interval after the PEEP stabilization period. Statistics. GraphPad Prism 5 (GraphPad Software Inc., San Diego, CA) was used for statistical analysis. All results were expressed as mean±standard error of mean (SEM). Statistical analysis was made by ttest or one-way analysis of variance (ANO-VA) for repeated measures followed by Bonferroni post hoc test. P value was considered significant if greater than 0.05. 
RESULTS
Effect of NaHS on hemodynamic parameters.
In the control group, the serial intravenous doses of NaHS did not significantly modify the mean arterial pressure(MAP) ( Figure  2, panel A) , and the HR. In the ischemiainduced group, the increase in intra-thoracic pressures caused a significant reduction in MAP (Figure 2, panel B) associated with not-significant changes in HR. After incremental bolus of NaHS, MAP values progressively increased, recovering values comparable with the pre-ischemic measures after the 3 µg/kg bolus (p=0.03; Figure 2, panel B) . Gas exchange (pO 2 , pCO 2 ) and metabolic status (pH, lactate) did not change significantly during H 2 S infusion in both groups. In particular, mean (±SEM) PaCO 2 was 38.6±1.1 mmHg in control group and 37.9±0.9 in the experimental group. Effect of NaHS on perfusion of jeju- nal mucosa and sternal skin. The baseline flow did not differ between the two studied groups, neither in the mesenteric nor cutaneous districts (248 vs. 229 PU, p=0.8; 35.7 vs. 36.3 PU, p=0.8, respectively; Figure 3, panel A) . In the control group, jejunal mucosa perfusion increased with a peak at 10 µM/Kg (Figure 3, panel B) . Conversely, a not-significant effect was observed on the sternal skin, suggesting that NaHS did not affect the cutaneous microcirculation ( Figure 3, panel B ) (p<0.05). In the PEEP-induced ischemia group, the jejunal mucosa perfusion significantly decreased 66% from the baseline immediately after application of the PEEP (p=0.009, Figure  3 , panel C), whereas skin perfusion was not significantly affected, suggesting that PEEP application selectively impaired the mesenteric perfusion (Figure 3, panel C) . As observed in the control group, in the ischemia group the administration of NaHS significantly increased perfusion of jejunal mucosa, with a recovery of 70% of preischemic mesenteric flow (Figure 3, panel  D) (p<0.05) . Finally, ischemic animals showed higher increases in jejunal mucosa blood flow than animals in the control group (p=0.02, Figure 3 ).
DISCUSSION
Our study shows that NaHS, an H 2 S donor, can restore PEEP-mediated splanchnic hypoperfusion to 70% of pre-PEEP values. These results are important if considering that with the aim to improve splanchnic perfusion, the most widely utilized drugs are dopamine receptor agonists (dopamine or fenoldopam), since they are supposedly free from side effects (15, 16) but without definitive evidence of their beneficial role in intestinal mucosa perfusion (17) . We also observed that, in the control group, low concentrations of H 2 S were able to increase the intestinal mucosal perfusion up to 50% of the baseline blood flow. The H 2 S-induced vasodilatation appeared to be limited to the mesenteric micro-vascular district for two reasons: 1) it did not result in any clinically significant systemic hemodynamic effect; 2) it did not directly affect the cutaneous microcirculation, suggesting a tissueselectivity. Although H 2 S is known to have negative inotropic and chronotropic effects, the absence of a significant systemic hemodynamic change in our experiments can be explained by the acute administration of the compound, whereas the absence of metabolic modifications is in line with previous findings on the porcine ischemia/reperfusion model (18) . The H 2 S-induced improvement in mesenteric microcirculation perfusion was confirmed in PEEP-ischemic animals. PEEP produced a mesenteric hypo-perfusion, cutting down 66% of the mesenteric blood flow, consistent with previous studies (13, 14) . In this condition, the H 2 S-induced vascular relaxation was associated with a 70% restoration of the pre-ischemic mesenteric blood flow at NaHS dose of 1000 µg/kg ( Figure 3, panel C) . As could be expected, in the ischemic group, the mesenteric mucosa seemed to be more H 2 S-responsive than in the control group, especially at elevated doses (Figure 3, panel B and D) . Skin perfusion did not significantly change, suggesting that the effects of H 2 S were exerted mostly in the central blood compartment rather than in the peripheral circulation ( Figure 3, panel D) . Our findings confirmed the property of exogenous H 2 S in the mesenteric circulation of pigs, which was previously shown in small animal models (7) . As shown in Figure 3 (panels D) , there is a dip in the dose/effect curve. This seems to be far from a pure sigmoidal dose/effect curve, and is probably caused by the limited sample. Limitations of this study must be mentioned. Although our study provided proof of the concept of H 2 S-related marked improvement of mesenteric perfusion, it does not allow quantitative conclusions to be drawn about the effective increases in blood fl ow, not having an untreated ischemia group. Also, the decrease in splanchnic perfusion induced by PEEP may differ from other pathophysiology conditions resulting in splanchnic ischemia and may, therefore, show different reactions on the infusion of H 2 S-donors. Finally, we were not able to dose H 2 S, and its plasma concentration was only mathematically deduced.
CONCLUSION
Exogenous H 2 S-donor produced a tissueselective dilatation of the microcirculation capable of increasing blood fl ow in mesenteric mucosa both in normal and ischemic conditions, without affecting systemic hemodynamic parameters. Thus, we think that H 2 S could be a potentially useful compound available in critical conditions to reverse mesenteric hypoxia-reperfusion injury. Studies are needed to assess its effects on cell metabolism, its precise pharmacodynamics and pharmacokinetics, and to assess the safety of possible future clinical use.
